Also

A sleeping pill produced by Neurocrine Biosciences Inc. failed to win U.S. regulatory approval, sending shares of the San Diego-based company down 62%. The Food and Drug Administration needed more information before it could approve two dose levels of the drug, indiplon, and wouldn’t approve an extended-release version in a higher dose, Neurocrine said.